BJMO - volume 12, issue 8, december 2018
P. Specenier MD, PhD
The 2018 annual meeting of the European Society for Medical Oncology (ESMO) turned out to be a grand cru for head and neck cancer, with two abstracts in this disease entity presented during the presidential sessions of the meeting. These two presentations, one on the use of immune checkpoint inhibition in the frontline treatment of recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) and one evaluating treatment de-escalation in low-risk, p16-positive oropharyngeal cancer, form the lion’s share of this report. In addition to this data were presented of clinical trials looking at the potential of durvalumab plus danvatirsen, M7824, tipifarnib and SD-101 in the treatment of R/M SCCHN.
Read moreBJMO - volume 12, issue 7, november 2018
N. van den Eede , A. de Paepe MD, D. Strens , P. Specenier MD, PhD
We calculated the management costs from diagnosis to death of glioblastoma patients treated at the Antwerp University Hospital between 2007 and 2016. Overall, the average cost per patient from the health care payer’s perspective was €45,165 (95% confidence interval €37,204–€54,104). The major cost driving factor was hospitalisation.
(BELG J MED ONCOL 2018;12(7):334–338)
Read moreBJMO - volume 12, issue 6, october 2018
P. Specenier MD, PhD
Three inhibitors ALK-inhibitors have been assessed in six randomised phase III trials in patients with advanced anaplastic lymphoma kinase (ALK) positive Non Small-Cell Lung Cancer (NSCLC). Patient and tumour characteristics, efficacy, and safety results are summarised in Tables 1, 2, and 3, respectively. Progression-free survival was the primary endpoint in all trials. In first-line, alectinib was superior to crizotonib, and both crizotinib and ceritinib were superior to pemetrexed plus platinum. Crizotinib and ceritinib were superior to pemetrexed or docetaxel in previously treated patients.
(BELG J MED ONCOL 2018;12(6):275–278)
BJMO - volume 12, issue 6, october 2018
P. Specenier MD, PhD
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2018;12(6):301–302)
Read moreBJMO - volume 12, issue 5, september 2018
P. Specenier MD, PhD
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2018;12(5):263–264)
Read moreBJMO - volume 12, issue 4, august 2018
P. Specenier MD, PhD
This article will summarize the key data in the field of head and neck cancer presented during the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).
Read moreBJMO - volume 12, issue 3, may 2018
P. Specenier MD, PhD
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2018;12(3):145–146)
Read more
Top
